Ligand Pharmaceuticals Inc
LGNXZ- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000886163
In the last 90 days, Ligand Pharmaceuticals Inc insiders filed 0 open-market purchases and 6 sales; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Ligand Pharmaceuticals Inc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 6 filings
- 4 insiders, $16.1M in total
- Insiders trading
- 4
- Net value
- −$16.1M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Ligand Pharmaceuticals Inc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Zimmermann Martine | Director | 3,782 | Sep 24, 2026 | 3 |
| Reardon Andrew | CLO & Secretary | 36,514 | Sep 8, 2026 | 9 |
| Espinoza Octavio | Chief Financial Officer | 27,696 | Aug 14, 2026 | 11 |
| Haas Jason | Director | 3,981 | Aug 14, 2026 | 3 |
| Davis Todd C | Chief Executive Officer | 199,513 | Jul 6, 2026 | 4 |
| Sabba Stephen L | Director | 33,629 | Jun 18, 2026 | 4 |
| Lamattina John L | Director | 26,969 | Jun 12, 2026 | 4 |
| Aryeh Jason | Director | 102,580 | Jun 12, 2026 | 2 |
| Kozarich John W | Director | 42,622 | Jun 9, 2026 | 9 |
| Gray Nancy Ryan | Director | 8,930 | Jun 9, 2026 | 2 |
| Korenberg Matthew E | President & COO | 50,777 | Sep 24, 2024 | 0 |
| Higgins John L | Director | 417,695 | Dec 30, 2022 | 0 |
| Foehr Matthew W | Other: Former Executive Officer | 162,187 | Nov 3, 2022 | 0 |
| Berkman Charles S | Other: Former Executive Officer | 23,825 | Nov 3, 2022 | 0 |
| Patel Sunil | Other: Former Director | 28,820 | Nov 3, 2022 | 0 |
| Boyce Sarah | Other: Former Director | 2,892 | Nov 3, 2022 | 0 |
| Cochran Jennifer R. | Other: Former Director | 1,161 | Nov 3, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 17, 2024 (view filing) | May 15-17 | 2 days | Espinoza OctavioChief Financial Officer | SSale | −13.3K | $86.26 | −$1.15M | −36.2%23.4K after | 4 lots |
| May 15, 2024 (view filing) | May 13-14 | 2 days | Korenberg Matthew EPresident & Chief Operating | SSale | −17.6K | $84.99 | −$1.50M | −16.9%86.3K after | 3 lots |
| May 13, 2024 (view filing) | May 9 | 4 days | Reardon AndrewChief Legal Officer & | SSale | −10.0K | $83.04 | −$830.4K | −31.1%22.2K after | |
| Mar 7, 2024 (view filing) | Mar 5 | 2 days | Sabba Stephen LDirector | SSale | −1.89K | $74.30 | −$140.6K | −6.1%28.9K after | |
| Feb 29, 2024 (view filing) | Feb 28 | 1 day | Espinoza OctavioChief Financial Officer | SSale | −140 | $88.46 | −$12.4K | −0.5%29.8K after | |
| Sep 25, 2023 (view filing) | Sep 22 | 3 days | Davis Todd CCHIEF EXECUTIVE OFFICER | PPurchase | +4.00K | $59.38 | +$237.5K | +5.8%73.1K after | |
| May 18, 2023 (view filing) | May 16 | 2 days | Kozarich John WDirector | SSale | −4.44K | $77.20 | −$343.1K | −10.4%38.5K after | |
| May 12, 2023 (view filing) | May 10 | 2 days | Sabba Stephen LDirector | SSale | −6.41K | $77.13 | −$494.2K | −19.9%25.8K after | |
| May 10, 2023 (view filing) | May 8 | 2 days | Kozarich John WDirector | SSale | −6.41K | $76.56 | −$490.6K | −13.2%42.2K after | 2 lots |
| Mar 28, 2023 (view filing) | Mar 24 | 4 days | Reardon AndrewSee Remarks | SSale | −300 | $69.92 | −$21.0K | −1.8%16.3K after | |
| Dec 20, 2022 (view filing) | Dec 16 | 4 days | Higgins John LDirector | SSale | −10.0K | $61.87 | −$618.7K | −2.3%423.0K after | |
| Nov 21, 2022 (view filing) | Nov 17 | 4 days | Higgins John LChief Executive Officer | SSale | −10.0K | $78.32 | −$783.2K | −2.3%416.7K after | |
| Nov 10, 2022 (view filing) | Nov 9 | 1 day | Espinoza OctavioChief Financial Officer | SSale | −1.70K | $75.64 | −$128.3K | −16.1%8.86K after | |
| Sep 22, 2022 (view filing) | Sep 16 | 6 days | Higgins John LChief Executive Officer | SSale | −1.00K | $88.06 | −$88.1K | −0.3%366.2K after | Amended |
| Sep 16, 2022 (view filing) | Sep 15 | 1 day | Higgins John LChief Executive Officer | SSale | −2.00K | $90.00 | −$180.0K | −0.5%367.2K after | From original |
| May 13, 2022 (view filing) | May 13 | Same day | Foehr Matthew WPresident and COO | PPurchase | +2.50K | $82.76 | +$206.9K | +1.5%173.4K after | |
| May 10, 2022 (view filing)5:33 PM ET | May 10 | Same day | Higgins John LChief Executive Officer | SSale0.75% Convertible Senior Notes due 2023 | – | – | – | – | DerivativePrice outlier |
| Mar 1, 2022 (view filing) | Feb 28 | 1 day | Kozarich John WDirector | SSale | −908 | $102.62 | −$93.2K | −2.2%41.2K after | |
| Nov 17, 2021 (view filing) | Nov 16 | 1 day | Lamattina John LDirector | SSale | −4.83K | $161.86 | −$782.6K | −16.0%25.4K after | |
| Nov 12, 2021 (view filing) | Nov 12 | Same day | Higgins John LChief Executive Officer | SSale | −3.00K | $160.50 | −$481.5K | −0.9%335.1K after | |
| Nov 12, 2021 (view filing) | Nov 11 | 1 day | Foehr Matthew WPresident and COO | SSale | −11.2K | $163.02 | −$1.82M | −6.3%166.5K after | |
| Aug 5, 2021 (view filing) | Aug 4 | 1 day | Foehr Matthew WPresident and COO | SSale | −8.84K | $109.67 | −$969.5K | −5.1%164.4K after |